STOCKSCREENR

0HD2.L

LSE

Alnylam Pharmaceuticals, Inc.

$319.08+22.38(+7.54%)Mkt Cap: $42.32B

Key Stats

Market Cap

$42.32B

P/E Ratio

-42.60

EPS

$-7.49

Dividend Yield

0.00%

52-Week Range

$143.66 — $319.08

Volume

2

Avg Volume

1.44K

Beta

0.38

Price Alerts for 0HD2.L

Get alerted when 0HD2.L hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-42.60

Forward P/E

44.33

PEG Ratio

0.20

P/S (TTM)

11.06

P/B (TTM)

51.89

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

0.90%

ROA (TTM)

0.06%

ROIC

—

Gross Margin

0.82%

Operating Margin

0.14%

Net Margin

—

Debt/Equity

1.62

Current Ratio

2.76

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.24%

EPS Growth (5Y)

+0.17%

Sales Growth (3Y)

+0.41%

Sales Growth (5Y)

+0.64%

EPS Est (This Year)

$7.20

EPS Est (Next Year)

$11.94

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$22.00

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

132.62M

Float

131.45M

Free Float %

99.11%

Technicals

RSI (14)

33.29

SMA 20

$349.88

SMA 50

$388.53

SMA 200

$403.01

ATR (14)

10.72

Volatility (Week)

0.03%

Volatility (Month)

0.03%

Pattern

Doji

Performance

1 Day

-0.39%

1 Week

-7.63%

1 Month

-19.73%

3 Months

-27.31%

6 Months

-25.80%

1 Year

—

YTD

-19.58%

All-Time High

$495.00

About

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

LSE

IPO Date

2018-01-29

Employees

2230

CEO

Yvonne L. Greenstreet

Index Membership

—

Website

https://www.alnylam.com

Alnylam Pharmaceuticals, Inc. (0HD2.L) is a healthcare company in the medical - pharmaceuticals industry listed on the LSE. With a market capitalization of $42.32B, a P/E ratio of -42.60, 0HD2.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare 0HD2.L against other stocks using dozens of fundamental and technical filters.

Similar Stocks

0QZU.L

Vertex Pharmaceuticals Incorporated

$434.30

+1.15%

$111.62B

0R2M.L

Regeneron Pharmaceuticals, Inc.

$709.00

+0.82%

$76.60B

0M3Q.L

Zoetis Inc.

$115.60

+1.72%

$55.54B

0RD1.L

Camurus AB (publ)

$530.55

+0.06%

$31.64B

0JAV.L

Insmed Incorporated

$136.55

+1.81%

$29.44B

0JDM.L

IQVIA Holdings Inc.

$158.90

+1.74%

$26.97B

Frequently Asked Questions

What is Alnylam Pharmaceuticals, Inc.'s P/E ratio?

Alnylam Pharmaceuticals, Inc. (0HD2.L) has a trailing twelve-month (TTM) P/E ratio of -42.60. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Alnylam Pharmaceuticals, Inc. pay a dividend?

No, Alnylam Pharmaceuticals, Inc. (0HD2.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Alnylam Pharmaceuticals, Inc.'s market cap?

Alnylam Pharmaceuticals, Inc. (0HD2.L) has a market capitalization of $42.32 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.

How has 0HD2.L performed this year?

Alnylam Pharmaceuticals, Inc. (0HD2.L) has returned -19.58% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.